The objective of the BOOM-IBD2 clinical trial is to evaluate the effectiveness of an investigational nerve stimulation (neuromodulation) device for ulcerative colitis (UC). This treatment involves implanting a small electronic device that delivers mild electrical pulses to a nerve near the tailbone. The study will assess the impact of this therapy on bowel urgency, quality of life, inflammation, and other measures over a 12-month period through a combination of in-person and virtual visits.

To create a high-risk for inflammatory bowel disease research cohort, by enrolling individuals who have a first-degree relative (parent sibling, or child) with inflammatory bowel disease (IBD; including Crohn’s disease, ulcerative colitis, or IBD unclassified/indeterminate colitis), but who do not have one of these diseases themselves.

To monitor behaviors, diet, and biomarkers of IBD in these unaffected first-degree relatives over time, to better understand how to predict and prevent the development of IBD in high-risk individuals.

To demonstrate the effectiveness of the investigational drug GS-5290, compared to placebo control, in achieving Clinical Response at Week 12

The objective of this study is to assess the PK, efficacy, and safety of the investigational drug in pediatric patients with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to aminosalicylates, oral locally acting corticosteroids, systemic corticosteroids, immunosuppressants, and/or biologic therapies.

To determine the effect of dual targeted therapy with an anti-integrin (VDZ) and a JAK inhibitor (TOF) on clinical remission.

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD).

The objective of the STENOVA study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of the study drug AGMB-129 in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures.

The purpose of this study is to continuously monitor a patient's IBD biomarkers with the non-invasive IBD AWARE® wearable device to determine its effectiveness in monitoring IBD inflammation. We also aim to understand how these inflammatory biomarkers relate to your symptoms. By participating, you'll help us enhance the way we monitor and manage IBD. 

To our knowledge, the use of a timed modified Mediterranean diet (combining the Mediterranean diet with timed eating) has not been previously investigated in humans. We hypothesise that combining timed eating and the Mediterranean diet will improve inflammation and gut leakiness in patients with IBD as compared to the Mediterranean diet by itself and with no intervention. 

The purpose of this study is to evaluate the safety and efficacy of the investigational drug MORF-057 in participants with moderately to severely active Ulcerative Colitis.